Docetaxel Plus Gemcitabine Promising in Advanced Pancreatic Cancer
ORLANDO-In a randomized multicenter phase II study of advanced pancreatic carcinoma by the European Organization for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Group, the combination of docetaxel (Taxotere) and gemcitabine (Gemzar) was "promising" relative to docetaxel/cisplatin (Platinol), Manfred P. Lutz, MD, of University Hospital, Ulm, Germany, said at the 38th Annual Meeting of the American Society of Clinical Oncology (abstract 498).
ORLANDOIn a randomized multicenter phase II study of advanced pancreatic carcinoma by the European Organization for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Group, the combination of docetaxel (Taxotere) and gemcitabine (Gemzar) was "promising" relative to docetaxel/cisplatin (Platinol), Manfred P. Lutz, MD, of University Hospital, Ulm, Germany, said at the 38th Annual Meeting of the American Society of Clinical Oncology (abstract 498).
"Both combinations are active in advanced pancreatic cancer, and both have acceptable toxicities," Dr. Lutz said.
Although gemcitabine is widely used for the treatment of advanced pancreatic cancer, he said, response rates when used as a single agent are less than 10%, and median survival is less than 6 months. Both docetaxel and cisplatin also have proven clinical activity in this disease and are synergistic with gemcitabine in peclinical models.
The trial enrolled 96 patients at 17 centers. Patients received gemcitabine 800 mg/m2 on days l and 8 and docetaxel 85 mg/m2 on day 8, every 21 days, or docetaxel 75 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1, every 21 days.
The most important toxicity was neutropenia, which occurred in approximately 30% of patients. Febrile neutropenia was seen in 17% of patients on docetaxel/cisplatin and 7% on docetaxel/gemcitabine. There was more neuropathy and vomiting in the docetaxel/cisplatin arm.
Partial responses were confirmed in 6 of 38 evaluable patients in the docetaxel/gemcitabine arm (15.8%) and in 5 of 31 evaluable patients in the docetaxel/cisplatin arm (16.1%). Progression-free survival was 3.6 months with gemcitabine and 2.8 months with cisplatin. Median survival (intent to treat) was 7.4 months and 6.3 months, respectively. "One-year survival is roughly 30% for gemcitabine/docetaxel," Dr. Lutz said.
He noted that toxicity in both arms is predictable and manageable. "However," he said, "gemcitabine/docetaxel seems to have the favorable toxicity profile." The docetaxel/gemcitabine combination will be tested against gemcitabine alone in a randomized phase III trial.
